Comparable stake leader
Sire Group Ltd.
SEC ownership of TITAN PHARMACEUTICALS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000910267.
Disclosed value leader
Sire Group Ltd.
Comparable rows
0/17
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Sire Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000910267
- Issuer location
- San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of TITAN PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sire Group Ltd.
Disclosed value leader
Sire Group Ltd.
Comparable rows
0/17
Latest evidence
30 Jun 2026
3/4/5
13F
Highest disclosed value: $25,628,607
17 rows are not safely comparable across share classes.
Showing 1-8 of 17 holder rows.
Quick read
Sire Group Ltd. has the largest disclosed position value at $25.63M.
0 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sire Group Ltd.'s linked filing trail.
Disclosed position value
Top 5
Sire Group Ltd.
$25.63M
Choon Choong Hau
$4.68M
David E. Lazar
$123K
David Natan
$81.5K
Eric Howard Greenberg
$81.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sire Group Ltd. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$25,628,607
20,836,266 shares
|
— | 13 Sep 2023 |
| Choon Choong Hau |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$4,676,583
3,802,100 shares
|
— | 18 Mar 2024 |
| David E. Lazar |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
$123,000
100,000 shares
|
— | 26 Jul 2023 |
| David Natan |
3/4/5
Director
|
—
mixed-class rows
|
$81,488
166,250 shares
mixed-class rows
|
— | 25 Oct 2023 |
| Eric Howard Greenberg |
3/4/5
Director
|
—
mixed-class rows
|
$81,488
166,250 shares
mixed-class rows
|
— | 25 Oct 2023 |
| Katherine Beebe DeVarney |
3/4/5
President and COO, Director
|
—
mixed-class rows
|
$81,488
166,250 shares
mixed-class rows
|
— | 25 Oct 2023 |
| Matthew Charles McMurdo |
3/4/5
Director
|
—
mixed-class rows
|
$81,488
166,250 shares
mixed-class rows
|
— | 25 Oct 2023 |
| James R. McNab |
3/4/5
Director
|
—
mixed-class rows
|
$64,809
62,690 shares
mixed-class rows
|
— | 28 Jan 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to TITAN PHARMACEUTICALS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Sire Group Ltd.
Net 12M change
$0
Latest report
01 Oct 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sire Group Ltd. | 10%+ Owner | $25,628,607 | Mixed | 13 Sep 2023 | ||
| Choon Choong Hau | 10%+ Owner | $4,676,583 | Mixed | 18 Mar 2024 | ||
| David E. Lazar | Chief Executive Officer, Director | $123,000 | Mixed | 26 Jul 2023 | ||
| Katherine Beebe DeVarney | President and COO, Director | $81,488 | Mixed | 25 Oct 2023 | ||
| Matthew Charles McMurdo | Director | $81,488 | Mixed | 25 Oct 2023 | ||
| Eric Howard Greenberg | Director | $81,488 | Mixed | 25 Oct 2023 | ||
| David Natan | Director | $81,488 | Mixed | 25 Oct 2023 | ||
| James R. McNab | Director | $64,809 | Mixed | 28 Jan 2022 | ||
| Peter L. Chasey | Director | $61,500 | Mixed | 26 Jul 2023 | ||
| Avraham Ben-Tzvi | Director | $0 | Mixed | 01 Oct 2025 | ||
| Francisco Osvaldo Flores Garcia | Director | $0 | Mixed | 02 Apr 2024 | ||
| Firdauz Mokhtar | Director | $0 | Mixed | 02 Apr 2024 | ||
| Chay Weei Jye | Chief Executive Officer | $0 | Mixed | 20 Mar 2025 | ||
| Gabriel Loh | Director | $0 | Mixed | 27 Mar 2025 | ||
| Marc Rubin | Executive Chairman, Director | Mixed | 05 Jan 2022 | |||
| Joseph A. Akers | Director | Mixed | 05 Jan 2022 | |||
| Brynner Zet Han Chiam | Director | Mixed | 12 Oct 2023 | |||
| M. David Macfarlane | Director | Mixed | 05 Jan 2022 |
Recent insider transactions for TITAN PHARMACEUTICALS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Avraham Ben-Tzvi | TTNP | Common Stock | Disposed to Issuer | -100% | -3,313 | 0 | 01 Oct 2025 | Direct | ||
| Avraham Ben-Tzvi | TTNP | Option to Purchase Common Stock | Disposed to Issuer | -100% | -6,250 | 0 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.